Clinical Trial Update: To Assess Efficacy and Safety of Oral Reparixin in Patients With Fatigue and Locally Advanced / Metastatic Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial of oral reparixin for fatigue and locally advanced or metastatic breast cancer has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Reparixin (reparixin)

Snippet

Sponsor: Dompé Farmaceutici S.p.A | Conditions: Fatigue, Locally Advanced or Metastatic Breast Cancer | Phase 2 | Status: WITHDRAWN